Belite Bio Inc ADR (BLTE) — Defensive Interval Ratio

Latest as of December 2025: 5179 days

Belite Bio Inc ADR (BLTE) has a Defensive Interval Ratio of 5179 days as of December 2025. Defensive assets of $140.21 Million (cash $-, short-term investments $139.49 Million, receivables $718.00K) cover 5179 days of daily cash needs of $27.07K/day. Check Belite Bio Inc ADR tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Defensive Interval Ratio

5179 days
Days of operational coverage

Defensive Assets

$140.21 Million
Cash + ST Investments + Receivables

Daily Cash Need

$27.07K
Current Liabilities ÷ 365

Current Liabilities

$9.88 Million
USD

Belite Bio Inc ADR Defensive Interval Ratio (2020–2025)

This chart shows how Belite Bio Inc ADR's Defensive Interval Ratio has evolved across 6 annual periods from 2020 to 2025. As of December 2025, the ratio stands at 5179 days, meaning defensive assets of $140.21 Million can fund 5179 days of operations without new revenue. Also explore Belite Bio Inc ADR equity growth rate to track the company's year-over-year net asset growth rate.

Annual Defensive Interval Ratio for Belite Bio Inc ADR (2020–2025)

The table below presents the year-by-year Defensive Interval Ratio for Belite Bio Inc ADR from 2020 to 2025, covering 6 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see market cap of Belite Bio Inc ADR.

Year DIR (days) Defensive Assets (USD) Daily Cash Need Cash ST Investments Change (days)
2025 5179 days $140.21 Million $27.07K/day $- $139.49 Million ▼ -1703 days
2024 6882 days $114.07 Million $16.58K/day $- $113.47 Million ▲ +6795 days
2023 87 days $867.00K $9.95K/day $- $0.00 ▲ +84 days
2022 3 days $19.00K $5.76K/day $- $- ▼ -2 days
2021 5 days $23.00K $4.48K/day $- $- ▼ -10 days
2020 15 days $40.00K $2.66K/day $- $-
DIR = (Cash + Short-term Investments + Net Receivables) / (Daily Cash Expenses)